News | Cardiac Resynchronization Therapy Devices (CRT) | April 14, 2017

NICE Recommends Boston Scientific CRT-Ds With EnduraLife Battery Technology for Heart Failure Treatment

Extended battery life of Boston Scientific devices attributed to reduction in replacement procedures and complications; has potential for significant cost savings

NICE Recommends Boston Scientific CRT-Ds With EnduraLife Battery Technology for Heart Failure Treatment

April 14, 2017 — The National Institute for Health and Care Excellence (NICE) recently issued medical technology guidance recommending the use of Boston Scientific Corp. cardiac resynchronization therapy defibrillators (CRT-D) powered by EnduraLife Battery Technology for treating patients with heart failure.

In their evaluation, NICE – which provides evidenced-based guidance to improve health and social care in the National Health Service (NHS) in the United Kingdom – concluded that the extended battery life observed with Boston Scientific EnduraLife-powered CRT-Ds is likely to reduce the number of avoidable replacement procedures a patient may have to undergo, thereby offering improved outcomes for patients and potential savings to the NHS in England of approximately £6 million in the first five years.

The savings were calculated by modeling the costs associated with early replacement procedures, such as a reduction in hospital admissions, bed days and procurement costs. Fewer replacement procedures also equate to a reduction in associated costs accrued from post-operative complications and infections – both of which also have a measurable impact on morbidity and mortality.

"The NICE guidance reinforces the multi-faceted importance of battery longevity in devices treating patients with heart failure and life-threatening ventricular arrhythmias," said Jay Wright, M.D., consultant cardiologist, Liverpool Heart and Chest Hospital, Liverpool, U.K. "Additionally, the reduction in replacement procedures and potential savings identified within the guidance could offer longer-term relief to NHS providers who have recently seen an increase in the number of patients requiring further in-hospital treatment."  

The NICE medical technologies advisory committee found that the evidence from 16 independent clinical and economic studies supported a case for adoption. The committee concluded that EnduraLife-powered CRT-Ds have a greater battery capacity and longer battery life compared with other CRT-Ds reviewed.

The full guidance document can be read here.

For more information: www.bostonscientific.com

Related Content

Feature | Inventory Management| April 28, 2017 | Dave Fornell
Tracking cardiovascular device inventory in cath labs, electrophysiology (EP) labs and operating rooms (ORs) can be a
AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
News | Left Atrial Appendage (LAA) Occluders| April 25, 2017
AtriCure Inc. announced it has sold more than 100,000 AtriClip Left Atrial Appendage Exclusion System devices worldwide...
Clinical Study Validates Efficiencies of Stereotaxis Niobe ES System Over Niobe II System
News | Robotic Systems| April 24, 2017
A recent study conducted at Centre Hospitalier Universitaire (CHU) of Saint-Étienne, France validated the advantages of...
Digital Health Company Murj Announces $4.5 Million in Financing
News | Implantable Cardiac Monitor (ICM)| April 19, 2017
Murj Inc., a digital health company that helps manage implantable cardiac device data, announced more than $4.5 million...
The Unify ICD is one of the SJM devices in an FDA warning letter
Feature | Implantable Cardioverter Defibrillators (ICD)| April 14, 2017 | Dave Fornell
April 14, 2017 — The U.S. Food and Drug Administration (FDA) sent a warning letter to Abbott/St.
An electrophysiology EP ablation procedure to treat a heart arrhythmia
Feature | HRS| April 14, 2017
April 14, 2017 — The Heart Rhythm Society (HRS) has announced its late-breaking clinical trials at its annual meeting
Vascular Dynamics Completes $10.4 Million Financing for MobiusHD System
News | Hypertension| April 13, 2017
Vascular Dynamics Inc. (VDI) a privately held medical device company developing novel solutions for the treatment of...
The Arctic Front Advance Cardiac CryoAblation Catheter treats atrial fibrillation with pulmonary vein isolation
News | Atrial Fibrillation| April 11, 2017
April 10, 2017 — Medtronic recently announced the first enrollments in the STOP Persistent AF clinical trial.
Sponsored Content | Videos | EP Lab| April 10, 2017
A discussion with Heart Rhythm Society (HRS) President Michael Gold, M.D., Ph.D., director of cardiology and associat
SCAI, MEDCAC panel, health outcomes, heart failure, treatment technologies
News | Heart Failure| April 04, 2017
This week the Centers for Medicare & Medicaid Services (CMS) convened a panel of the Medicare Evidence Development...
Overlay Init